Latest Conference Articles

Amil Shah, MD, of Harvard Medical School, discusses the utilization of echocardiography - often the first step for the indication of heart failure with preserved ejection fraction - to diagnose patients with the condition and separate them from other morbidities.

James Udelson, MD, the chief of cardiology at Tufts Medical Center, discusses the possibilities offered by the development of subcutaneous furosemide for HF patients in need of diuresis.

Charles L Raison, MD, explains the relationship between mental health and the trillions of microorganisms that live in and on our bodies.

David Boyer, MD, talks about the topline results from a prospective, double-masked phase 2b clinical trial evaluating ALG-1001 compared to Bevacizumab in patients with DME.

Raj Maturi, MD, talks about the use of sirolimus in combination with aflibercept for patients with chronic AMD.

The phase 2 trial results were very positive in regards to its safety endpoints and the efficacy endpoints were very encouraging.

Companies are skirting regulation to be the first to build the next big stem cell therapy, creating clinical concerns and poor patient outcomes.

Intravitreal ranibizumab significantly improved BCVA compared with vPDT for patients with myopic CNV, often after only 1 or 2 injections.

Jay Prensky, MD, talks about the results of the PALADIN real-world study and the use of the fluocinolone acetonide 0.2 ug/day implant in DME patients.

Carl Baker, MD, speaks about factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or Ranibizumab.

Rishi Singh, MD, talks about the prevention of macular edema in patients with diabetic retinopathy undergoing cataract surgery with an intravitreal aflibercept injection.

Jay Prensky, MD, talks about the pluses and clinical implications of doing real-world observational studies as opposed to clinical trials.

Aflibercept reduced macular edema, microaneurysms, leakage, and ischemic burden while improving VA for patients with DME or RVO.

Rishi Singh, MD, talks about the need for a standard definition of identifying macular edema in diabetic patients.

Thomas Ciulla speaks about the “real-world” outcomes for anti-VEGF therapy in patients with diabetic macular edema (DME) in the United States.

The device uses an efficient, user-friendly, smart algorithm to measure contrast function.

Sirolimus plus aflibercept showed marked reduction in intraretinal and subretinal fluid compared with aflibercept alone for patients with wet AMD.

Rajeev Muni speaks about the 1-year results of a randomized trial comparing Pneumatic Retinopexy vs. Vitrectomy in the management of primary Rhegmatogenous Retinal Detachment.

The drug is being tested as a potential nAMD combination therapy with ranibizumab.

In an analysis of dosing subgroups through 96 weeks of the VIEW 1 and 2 trials, aflibercept injections showed similar results in meeting visual acuity endpoints to ranibizumab.

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Pravin Dugel, MD, talks about the study results for OPT-302 and the possibilities that further data could provide for DME, nAMD, and diabetic retinopathy.

Patients taking 440µg doses of the drug saw better results than those treated with 44µg doses

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

Patients experienced prolonged time to treatment failure, meeting primary endpoints in VISUAL I and II trials.

Improvements in visual acuity were less pronounced in the "real-world" setting compared with randomized trials for diabetic macular edema.

Jeffrey Luttrull, MD, speaks about the reduced risk of choroidal neovascularization following use of the subthreshold diode micropulse laser (SDM) retinal protective therapy™ (RPT) for patients with Dry AMD.

Jeffrey Heier talks about RGX-314 gene therapy and the advantages of subretinal delivery.

Patients treated with C3F8 saw a superlative 84% release rate, according to study authors.

RGX-314 could help to alleviate the overall treatment burden for patients with wet age-related macular degeneration via a one-time subretinal injection.